SIGLEC17P: A Potential Drug Target for Synaptic Plasticity and Neurotransmission

Target Name: SIGLEC17P

NCBI ID: G284367

SIGLEC17P

Other Name(s): SIGLECP2 | HSPC078 | SIGLECP3 | Sialic acid binding Ig like lectin 17, pseudogene, transcript variant 1 | sialic acid binding Ig like lectin 17, pseudogene

SIGLEC17P: A Potential Drug Target for Synaptic Plasticity and Neurotransmission

SIGLEC17P (SIGLECP2) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the SIGLEC family of proteins, which are known for their role in intracellular signaling. SIGLEC17P is unique because it is a sphingomyelin-rich protein, which means it is rich in the amino acid sphingomyelin. Sphingomyelin is a major component of cell membranes and is known for its role in maintaining the structural integrity of cells.

SIGLEC17P is involved in a number of different processes in the brain, including the regulation of synaptic plasticity, the development and maintenance of neural networks, and the regulation of neurotransmitter release. It is also involved in the formation of tight junctions, which are a type of cell-cell barrier that helps to maintain the integrity of the blood-brain barrier.

One of the things that makes SIGLEC17P so interesting as a drug target is its role in the regulation of synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt in response to experience, and it is an important factor in the development and maintenance of learning and memory. SIGLEC17P is involved in the regulation of synaptic plasticity by helping to maintain the structural integrity of the brain's neural networks.

Another way that SIGLEC17P could be used as a drug target is its role in the regulation of neurotransmitter release. Neurotransmitters are chemical messengers that are used by the brain to communicate with other cells and to regulate various physiological processes. SIGLEC17P is involved in the regulation of neurotransmitter release by helping to maintain the structural integrity of the brain's endocytosis system.

SIGLEC17P is also involved in the formation of tight junctions, which are a type of cell-cell barrier that helps to maintain the integrity of the blood-brain barrier. The blood-brain barrier is a specialized barrier that helps to protect the brain from harmful substances that are released from the bloodstream. SIGLEC17P is involved in the formation of tight junctions by helping to regulate the movement of proteins into the brain.

In conclusion, SIGLEC17P is a protein that is involved in a number of different processes in the brain. Its unique role as a sphingomyelin-rich protein and its involvement in the regulation of synaptic plasticity, neurotransmission and tight junction formation make it an attractive drug target. Further studies are needed to fully understand the role of SIGLEC17P in the brain and its potential as a drug.

Protein Name: Sialic Acid Binding Ig Like Lectin 17, Pseudogene

The "SIGLEC17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets